Characteristic | Total Group (N = 160*) | Intervention Group (N = 81) | Control Group (N = 79) |
---|---|---|---|
Mean age | 63 | 63 | 64 |
Female | 28% | 27% | 28% |
Race: | Â | Â | Â |
   White | 86% | 88% | 84% |
   Black | 10% | 10% | 10% |
Education: | Â | Â | Â |
   At least some college | 90% | 98% | 82%†|
Enrolled in a prescription drug plan | 90% | 91% | 89% |
Missed medicine in the last month: | Â | Â | Â |
   Less than 5% of time | 92% | 90% | 95% |
   6-25% of time | 4% | 4% | 3% |
   26-50% of time | 2% | 3% | 2% |
   51-75% of time | 0% | 0% | 0% |
   76-95% of time | 1% | 1% | 0% |
   More than 95% of time | 1% | 1% | 0% |
Have potentially modifiable CHD risk factors: | Â | Â | Â |
   Blood pressure > 140/90 (mmHg) | 36% | 35% | 37% |
   Total cholesterol/HDL ratio > 4 | 54% | 53% | 51% |
   Smoker | 13% | 14% | 13% |
   Not using aspirin, but eligible for it | 50% | 54% | 47% |
Mean systolic blood pressure (mmHg) | 136.9 | 136.2 | 137.6 |
Mean diastolic blood pressure(mmHg) | 81.0 | 81.5 | 80.4 |
Mean total cholesterol (mg/dL) | 201.1 | 204.9 | 197.1 |
Mean HDL cholesterol (mg/dL) | 53 | 54.1 | 51.9 |
Mean predicted CHD risk over 10 yrs | 11.3 | 11.2 | 11.4 |
# of possible intervention options for CHD risk:‡ |  |  |  |
   0 | 10% | 12% | 8% |
   1 | 28% | 28% | 27% |
   2 | 47% | 40% | 54% |
   3 | 16% | 20% | 11% |
   4 | 0% | 0% | 0% |
Have self-efficacy to lower at least 1 CHD risk factor | 98% | 99% | 96% |
Are planning best evidence interventions§ | 27% | 28% | 25% |